Science for the benefit of cancer research.
At the Weizmann Institute of Science, more than 50 research groups focus on developing better ways to prevent, diagnose, and treat cancer. In fact, nearly half of Weizmann’s life sciences research is cancer-related. Institute research has provided critical knowledge about cancer in general—Weizmann scientists were the first to demonstrate that cancer can grow in stages—as well as about specific cancers, such as breast, lung, and prostate. The Institute’s collaborative teams are working to turn basic research into powerful diagnostic tools, drugs, and therapies to fight cancer—and win.
Weizmann scientists invented the synergistic effect behind Erbitux®, an antibody-based therapy that presents synergism with conventional chemotherapy. Used to treat colorectal and head and neck cancer, Erbitux® was approved by the FDA in 2001.
Weizmann scientist Prof. Yair Reisner tackled the problem of bone marrow transplantation between incompatible donors and recipients by using a hormone to mobilize the bone marrow cells of leukemia patients and “bubble” children. In 1993, this method was used for the first time to treat a leukemia patient in Italy. Today it is used worldwide.
A Weizmann scientist identified an enzyme that helps protect against lung cancer. Genetic differences may explain why some people get cancer while others, including smokers, don’t. A simple blood test could help gauge personal risk.
Weizmann Institute scientists are conducting pioneering research on the viability of photodynamic therapy (PDT) to treat malignant tumors. This “green” therapy can treat prostate cancer by combining non-toxic drug treatment with light, destroying the tumor’s blood supply. Clinical testing is underway.
Weizmann research established the foundation for the development of Gleevec®, which has been approved by the FDA to treat chronic myelogenous leukemia (CML).
When you support Weizmann Institute scientists that inspire you with their vital work, and encourage others to join your effort, you become partners in the search for meaningful solutions to the world's greatest challenges.
The Weizmann Institute believes that a fresh perspective on fighting cancer is needed: one that looks at cancer from all angles and tailors therapy to each person's specific illness. Introducing the bold new Integrated Cancer Center, a holistic approach to our complicated cancer problem.
Skin cancer – the most common cancer in the U.S. – is difficult to fight once it develops. In particular, melanomas tend to be fast-moving and all-too-frequently fatal. That's why the Weizmann Institute is investigating skin cancer from a number of perspectives, including genetic mutations and resistance to treatment.
©2019 American Committee for the Weizmann Institute of Science
